Versant Venture Management, LLC: 13F holdings
CIK 15600092026Q2
| Positions | 8 |
|---|---|
| Reported value | $162.6m |
| Filed | 2026-08-12 |
Top 10 holdings
| Security | Shares | Value | Weight |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | 3,180,780 | $77.0m | 47.3% |
| Century Therapeutics, Inc. | 12,166,109 | $29.8m | 18.3% |
| Jade Biosciences, Inc. | 991,783 | $22.0m | 13.6% |
| Lenz Therapeutics, Inc. | 2,656,888 | $15.1m | 9.3% |
| Contineum Therapeutics, Inc. | 542,628 | $8.9m | 5.5% |
| CRISPR Therapeutics AG | 148,831 | $8.1m | 5.0% |
| Skye Bioscience, Inc. | 2,007,704 | $1.4m | 0.9% |
| Tempest Therapeutics, Inc. | 269,772 | $299,447 | 0.2% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1560009")Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.